<h4>Background</h4>The PROSPET-BX trial compared [<sup>68</sup>Ga]PSMA-11 PET/CT (PSMA-PET) with multiparametric MRI (mpMRI) in parallel in men with suspicion of prostate cancer (PCa) after at least one previously negative biopsy (ClinicalTrials.gov: NCT05297162; GR-2018-12366240). This evidence concerns the gene FOLH1 and Familial prostate cancer.